Article

Clofazimine Inhibits Human Kv1.3 Potassium Channel by Perturbing Calcium Oscillation in T Lymphocytes

Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
PLoS ONE (Impact Factor: 3.23). 02/2008; 3(12):e4009. DOI: 10.1371/journal.pone.0004009
Source: PubMed

ABSTRACT

The Kv1.3 potassium channel plays an essential role in effector memory T cells and has been implicated in several important autoimmune diseases including multiple sclerosis, psoriasis and type 1 diabetes. A number of potent small molecule inhibitors of Kv1.3 channel have been reported, some of which were found to be effective in various animal models of autoimmune diseases. We report herein the identification of clofazimine, a known anti-mycobacterial drug, as a novel inhibitor of human Kv1.3. Clofazimine was initially identified as an inhibitor of intracellular T cell receptor-mediated signaling leading to the transcriptional activation of human interleukin-2 gene in T cells from a screen of the Johns Hopkins Drug Library. A systematic mechanistic deconvolution revealed that clofazimine selectively blocked the Kv1.3 channel activity, perturbing the oscillation frequency of the calcium-release activated calcium channel, which in turn led to the inhibition of the calcineurin-NFAT signaling pathway. These effects of clofazimine provide the first line of experimental evidence in support of a causal relationship between Kv1.3 and calcium oscillation in human T cells. Furthermore, clofazimine was found to be effective in blocking human T cell-mediated skin graft rejection in an animal model in vivo. Together, these results suggest that clofazimine is a promising immunomodulatory drug candidate for treating a variety of autoimmune disorders.

Download full-text

Full-text

Available from: Suhel Parvez
  • Source
    • "It has been recently employed in combination with other anti-mycobacterial drugs to treat Mycobacterium avium infections in AIDS patients (Kemper et al., 1992)(Kemper et al., 1992) The immunosuppressive effects of clofazimine are widely reported in animal models (Bezerra et al., 2005; Zeis & Anderson, 1986). A recent systematic study of clofazimine with human T cells revealed that this drug actually is a Kv1.3 (KCNA3) channel blocker (Ren et al., 2008)(Ren et al., 2008) Kv1.3 potassium channel has emerged as an attractive focus for development of immunosuppressive drugs the channel plays a key role in activation and function of T cells and is crucial in many important autoimmune disorders. With time the new attributes and functions of clofazimine have been disclosed. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The binding of clofazimine to human serum albumin (HSA) was investigated by applying optical spectroscopy and molecular docking methods. Fluorescence quenching data revealed that clofazimine bind to protein with binding constant in the order of 104 M−1, with the increase in temperature Stern-Volmer quenching constants gradually decreased indicating quenching mode to be static. The UV-visible spectra showed increase in absorbance upon interaction of HSA with clofazimine which further reveals formation of the drug albumin complex. Thermodynamic parameters obtained from fluorescence data indicate that process is exothermic and spontaneous. Forster distance (Ro) obtained from fluorescence resonance energy transfer (FRET) is found to be 2.05nm.Clofazimine impelled rise in α-helical structure in HSA as observed from far-UV CD spectra while there are minor alterations in tertiary structure of the protein. Clofazimine interacts strongly with HSA inducing secondary structure in the protein and slight alterations in protein topology as suggested by Dynamic light scattering results. Moreover docking results indicate clofazimine binds to hydrophobic pocket near to the drug site II in HSA.
    Full-text · Article · Jan 2016 · Journal of biomolecular Structure & Dynamics
  • Source
    • "The selective action of these drugs on tumor cells is related to a synergistic effect of a higher expression of Kv1.3 and of an altered redox state of cancer cells. The fact that clofazimine is already used in the clinic for the treatment of e.g., leprosis (Ren et al., 2008) and shows an excellent safety profile supports the feasibility of targeting mtKv1.3 for therapy. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Several types of channels play a role in the maintenance of ion homeostasis in subcellular organelles including endoplasmatic reticulum, nucleus, lysosome, endosome, and mitochondria. Here we give a brief overview of the contribution of various mitochondrial and other organellar channels to cancer cell proliferation or death. Much attention is focused on channels involved in intracellular calcium signaling and on ion fluxes in the ATP-producing organelle mitochondria. Mitochondrial K(+) channels (Ca(2+)-dependent BKCa and IKCa, ATP-dependent KATP, Kv1.3, two-pore TWIK-related Acid-Sensitive K(+) channel-3 (TASK-3)), Ca(2+) uniporter MCU, Mg(2+)-permeable Mrs2, anion channels (voltage-dependent chloride channel VDAC, intracellular chloride channel CLIC) and the Permeability Transition Pore (MPTP) contribute importantly to the regulation of function in this organelle. Since mitochondria play a central role in apoptosis, modulation of their ion channels by pharmacological means may lead to death of cancer cells. The nuclear potassium channel Kv10.1 and the nuclear chloride channel CLIC4 as well as the endoplasmatic reticulum (ER)-located inositol 1,4,5-trisphosphate (IP3) receptor, the ER-located Ca(2+) depletion sensor STIM1 (stromal interaction molecule 1), a component of the store-operated Ca(2+) channel and the ER-resident TRPM8 are also mentioned. Furthermore, pharmacological tools affecting organellar channels and modulating cancer cell survival are discussed. The channels described in this review are summarized on Figure 1. Overall, the view is emerging that intracellular ion channels may represent a promising target for cancer treatment.
    Full-text · Article · Sep 2013 · Frontiers in Physiology
  • Source
    • "Most specific Kv1.3 blockers, including MgTX, are not blood brain barrier permeable, and thus have limited clinical usage. Clofazimine is a known anti-mycobacterial drug and recently was found to inhibit the Kv1.3 channel [34]. It readily penetrates the blood brain barrier and reaches the brain in concentrations sufficient to completely protect against GrB-mediated neurotoxicity as observed in our in vivo studies. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Increasing evidence supports a critical role of T cells in neurodegeneration associated with acute and subacute brain inflammatory disorders. Granzyme B (GrB), released by activated T cells, is a cytotoxic proteinase which may induce perforin-independent neurotoxicity. Here, we studied the mechanism of perforin-independent GrB toxicity by treating primary cultured human neuronal cells with recombinant GrB. GrBactivated the protease-activated receptor (PAR)-1 receptor on the neuronal cell surface leading to decreased intracellular cyclic AMP levels. This was followed by increased expression and translocation of the voltage gated potassium channel, Kv1.3 to the neuronal cell membrane. Similar expression of Kv1.3 was also seen in neurons of the cerebral cortex adjacent to active inflammatory lesions in patients with multiple sclerosis. Kv1.3 expression was followed by activation of Notch-1 resulting in neurotoxicity. Blocking PAR-1, Kv1.3 or Notch-1 activation using specific pharmacological inhibitors or siRNAs prevented GrB-induced neurotoxicity. Furthermore, clofazimine protected against GrB-induced neurotoxicity in rat hippocampus, in vivo. These observations indicate that GrB released from T cells induced neurotoxicity by interacting with the membrane bound Gi-coupled PAR-1 receptor and subsequently activated Kv1.3 and Notch-1. These pathways provide novel targets to treat T cell-mediated neuroinflammatory disorders. Kv1.3 is of particular interest since it is expressed on the cell surface, only under pathological circumstances, and early in the cascade of events making it an attractive therapeutic target.
    Full-text · Article · Aug 2012 · PLoS ONE
Show more